Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, randomized, two-arm parallel-group, placebo-controlled, double-blind, multi-centre trial to evaluate the safety, tolerability, anti-inflammatory and cardio-protective effects after intravenous and oral administration of KAND567 in ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention

Next Previous
Trial Profile

A Phase IIa, randomized, two-arm parallel-group, placebo-controlled, double-blind, multi-centre trial to evaluate the safety, tolerability, anti-inflammatory and cardio-protective effects after intravenous and oral administration of KAND567 in ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KAND-567 (Primary) ; KAND-567 (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction
  • Focus Adverse reactions
  • Acronyms FRACTAL
  • Sponsors Kancera

Most Recent Events

  • 02 Sep 2024 Results (71) assessing the safety and tolerability of intravenous and oral administration of the fractalkine inhibitor KAND567 as well as reducing signs of reperfusion injury in STEMI patients undergoing PPCI were presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology.
  • 06 Feb 2024 According to a Kancera media release, additional findings are planned to be reported during the second quarter 2024.
  • 06 Feb 2024 According to a Kancera media release, signals of cardio-protective effects seen in the FRACTAL study are very encouraging, and are established markers for the anticipated efficacy endpoints in upcoming phase IIb/III studies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top